Market Overview

Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research

Share:

Bio-Rad Laboratories, Inc. (NYSE: BIO) and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc. (NASDAQ: MYGN) today announced that they have partnered to develop and distribute high-quality immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.

Posted-In: News Contracts FDA

 

Related Articles (MYGN + BIO)

Around the Web, We're Loving...

Get Benzinga's Newsletters